Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation

Yoshinobu Aisa, Takehiko Mori, Tomonori Nakazato, Takayuki Shimizu, Rie Yamazaki, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. The calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus, cause hypomagnesemia by suppressing reabsorption of magnesium (Mg) from renal tubules. To assess whether the effect on Mg metabolism after allogeneic hematopoietic stem cell transplantation (HSCT) differs among calcineurin inhibitors, we prospectively evaluated the Mg metabolism in recipients of allogeneic HSCT who received CSA or tacrolimus Methods. Patients who underwent allogeneic HSCT were enrolled. CSA and tacrolimus were given by continuous infusion starting from day -1. Serum Mg and the total amount of urinary Mg excretion were measured once before starting of CSA or tacrolimus, and once weekly after HSCT for 4 weeks. Mg was supplemented with magnesium 1-aspartate by continuous infusion to maintain the serum Mg level > 1.4 mEq/L. Results. Thirty-six patients were evaluated (12 in the CSA group, 24 in the tacrolimus group). The serum Mg level began to decrease in both groups at the first week after HSCT, and the mean serum Mg levels were significantly lower in the tacrolimus group than in the CSA group from the first to the third week. The total amount of urinary Mg excretion and Mg supplementation began to increase in both groups at the second week after HSCT, and the amounts in the tacrolimus group were significantly higher than those in the CSA group. Conclusions. Although both calcineurin inhibitors increased urinary Mg excretion and caused hypomagnesemia shortly after HSCT, the effect was more significant with tacrolimus than with CSA. This observation may explain the higher incidence of renal impairment and encephalopathy in patients receiving tacrolimus.

Original languageEnglish
Pages (from-to)1046-1050
Number of pages5
JournalTransplantation
Volume80
Issue number8
DOIs
Publication statusPublished - 2005 Oct 27

Fingerprint

Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Magnesium
Tacrolimus
Cyclosporine
Serum
Brain Diseases
Aspartic Acid

Keywords

  • Cyclosporine A
  • Hematopoietic stem cell transplantation
  • Hypomagnesemia
  • Magnesium
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. / Aisa, Yoshinobu; Mori, Takehiko; Nakazato, Tomonori; Shimizu, Takayuki; Yamazaki, Rie; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Transplantation, Vol. 80, No. 8, 27.10.2005, p. 1046-1050.

Research output: Contribution to journalArticle

@article{43bba618529f4e2893bf52a8952e82f9,
title = "Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation",
abstract = "Background. The calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus, cause hypomagnesemia by suppressing reabsorption of magnesium (Mg) from renal tubules. To assess whether the effect on Mg metabolism after allogeneic hematopoietic stem cell transplantation (HSCT) differs among calcineurin inhibitors, we prospectively evaluated the Mg metabolism in recipients of allogeneic HSCT who received CSA or tacrolimus Methods. Patients who underwent allogeneic HSCT were enrolled. CSA and tacrolimus were given by continuous infusion starting from day -1. Serum Mg and the total amount of urinary Mg excretion were measured once before starting of CSA or tacrolimus, and once weekly after HSCT for 4 weeks. Mg was supplemented with magnesium 1-aspartate by continuous infusion to maintain the serum Mg level > 1.4 mEq/L. Results. Thirty-six patients were evaluated (12 in the CSA group, 24 in the tacrolimus group). The serum Mg level began to decrease in both groups at the first week after HSCT, and the mean serum Mg levels were significantly lower in the tacrolimus group than in the CSA group from the first to the third week. The total amount of urinary Mg excretion and Mg supplementation began to increase in both groups at the second week after HSCT, and the amounts in the tacrolimus group were significantly higher than those in the CSA group. Conclusions. Although both calcineurin inhibitors increased urinary Mg excretion and caused hypomagnesemia shortly after HSCT, the effect was more significant with tacrolimus than with CSA. This observation may explain the higher incidence of renal impairment and encephalopathy in patients receiving tacrolimus.",
keywords = "Cyclosporine A, Hematopoietic stem cell transplantation, Hypomagnesemia, Magnesium, Tacrolimus",
author = "Yoshinobu Aisa and Takehiko Mori and Tomonori Nakazato and Takayuki Shimizu and Rie Yamazaki and Yasuo Ikeda and Shinichiro Okamoto",
year = "2005",
month = "10",
day = "27",
doi = "10.1097/01.TP.0000174340.40585.D4",
language = "English",
volume = "80",
pages = "1046--1050",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation

AU - Aisa, Yoshinobu

AU - Mori, Takehiko

AU - Nakazato, Tomonori

AU - Shimizu, Takayuki

AU - Yamazaki, Rie

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2005/10/27

Y1 - 2005/10/27

N2 - Background. The calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus, cause hypomagnesemia by suppressing reabsorption of magnesium (Mg) from renal tubules. To assess whether the effect on Mg metabolism after allogeneic hematopoietic stem cell transplantation (HSCT) differs among calcineurin inhibitors, we prospectively evaluated the Mg metabolism in recipients of allogeneic HSCT who received CSA or tacrolimus Methods. Patients who underwent allogeneic HSCT were enrolled. CSA and tacrolimus were given by continuous infusion starting from day -1. Serum Mg and the total amount of urinary Mg excretion were measured once before starting of CSA or tacrolimus, and once weekly after HSCT for 4 weeks. Mg was supplemented with magnesium 1-aspartate by continuous infusion to maintain the serum Mg level > 1.4 mEq/L. Results. Thirty-six patients were evaluated (12 in the CSA group, 24 in the tacrolimus group). The serum Mg level began to decrease in both groups at the first week after HSCT, and the mean serum Mg levels were significantly lower in the tacrolimus group than in the CSA group from the first to the third week. The total amount of urinary Mg excretion and Mg supplementation began to increase in both groups at the second week after HSCT, and the amounts in the tacrolimus group were significantly higher than those in the CSA group. Conclusions. Although both calcineurin inhibitors increased urinary Mg excretion and caused hypomagnesemia shortly after HSCT, the effect was more significant with tacrolimus than with CSA. This observation may explain the higher incidence of renal impairment and encephalopathy in patients receiving tacrolimus.

AB - Background. The calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus, cause hypomagnesemia by suppressing reabsorption of magnesium (Mg) from renal tubules. To assess whether the effect on Mg metabolism after allogeneic hematopoietic stem cell transplantation (HSCT) differs among calcineurin inhibitors, we prospectively evaluated the Mg metabolism in recipients of allogeneic HSCT who received CSA or tacrolimus Methods. Patients who underwent allogeneic HSCT were enrolled. CSA and tacrolimus were given by continuous infusion starting from day -1. Serum Mg and the total amount of urinary Mg excretion were measured once before starting of CSA or tacrolimus, and once weekly after HSCT for 4 weeks. Mg was supplemented with magnesium 1-aspartate by continuous infusion to maintain the serum Mg level > 1.4 mEq/L. Results. Thirty-six patients were evaluated (12 in the CSA group, 24 in the tacrolimus group). The serum Mg level began to decrease in both groups at the first week after HSCT, and the mean serum Mg levels were significantly lower in the tacrolimus group than in the CSA group from the first to the third week. The total amount of urinary Mg excretion and Mg supplementation began to increase in both groups at the second week after HSCT, and the amounts in the tacrolimus group were significantly higher than those in the CSA group. Conclusions. Although both calcineurin inhibitors increased urinary Mg excretion and caused hypomagnesemia shortly after HSCT, the effect was more significant with tacrolimus than with CSA. This observation may explain the higher incidence of renal impairment and encephalopathy in patients receiving tacrolimus.

KW - Cyclosporine A

KW - Hematopoietic stem cell transplantation

KW - Hypomagnesemia

KW - Magnesium

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=27744558227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744558227&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000174340.40585.D4

DO - 10.1097/01.TP.0000174340.40585.D4

M3 - Article

C2 - 16278584

AN - SCOPUS:27744558227

VL - 80

SP - 1046

EP - 1050

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -